Patents by Inventor Brij B. Saxena
Brij B. Saxena has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8088757Abstract: The present invention relates to a method of treating cancer selected from the group of cancers consisting of prostate cancer, renal cancer, breast cancer, ovarian cancer, CNS cancer, melanoma, lung cancer, and bladder cancer. This method involves administering to a patient in need of such treatment a therapeutically effective amount of a betulinol derivative compound of Formula (I). Also disclosed are conjugated and immunoconjugated derivatives of the compound of Formula (I) as well as methods of making and using them.Type: GrantFiled: September 12, 2005Date of Patent: January 3, 2012Assignee: BioRings LLCInventors: Brij B. Saxena, Premila Rathnam
-
Patent number: 8008280Abstract: The present invention relates to methods of treating HIV-1 infection in a subject. These methods involve administering to the subject with HIV-1 infection a therapeutically effective amount of a conjugated or immunoconjugated betulinol derivative compound, or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to treat the subject for HIV-1 infection. Also disclosed are methods inhibiting HIV-1 activity in a cell. These methods involve providing a cell infected with HIV-1 and contacting the cell with a conjugated or immunoconjugated betulinol derivative compound, or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to inhibit HIV-1 activity in the cell.Type: GrantFiled: September 12, 2005Date of Patent: August 30, 2011Assignee: Biorings LLCInventors: Brij B. Saxena, Premila Rathnam
-
Publication number: 20090246254Abstract: The present invention relates to a non-hormonal, biocompatible, and biodegradable intravaginal device for the delivery of spermiostatic, spermicidal and anti-infectious agents. The present invention also relates to methods of contraception using such a device, as well as the prevention and treatment of sexually transmitted diseases and vaginal infections through the application of the device.Type: ApplicationFiled: April 3, 2009Publication date: October 1, 2009Inventors: Brij B. Saxena, Mukul Singh, Sidney Lerner
-
Patent number: 7563612Abstract: The present invention relates to a chimeric nucleic acid molecule encoding a fusion protein having a human lutropin hormone-receptor domain and a human chorionic gonadotropin-? subunit domain, the isolated human lutropin hormone-receptor/human chorionic gonadotropin-? fusion protein, and antibodies which recognize part or all the domains of the fusion protein. Also provided are compositions having the human lutropin hormone-receptor/human chorionic gonadotropin-? fusion protein and a pharmaceutical carrier and compositions including antibodies to the fusion protein and a pharmaceutical carrier.Type: GrantFiled: September 26, 2005Date of Patent: July 21, 2009Assignee: Cornell Research Foundation, Inc.Inventors: Brij B. Saxena, Premila Rathnam, Makul Singh, Meirong Hao
-
Publication number: 20090176753Abstract: The present invention relates to a method of treating cancer selected from the group of cancers consisting of prostate cancer, renal cancer, breast cancer, ovarian cancer, CNS cancer, melanoma, lung cancer, and bladder cancer. This method involves administering to a patient in need of such treatment a therapeutically effective amount of a betulinol derivative compound of Formula (I). Also disclosed are conjugated and immunoconjugated derivatives of the compound of Formula (I) as well as methods of making and using them.Type: ApplicationFiled: September 12, 2005Publication date: July 9, 2009Inventors: Brij B. Saxena, Premila Rathnam
-
Patent number: 7521064Abstract: The present invention relates to a non-hormonal, biocompatible, and biodegradable intravaginal device for the delivery of spermiostatic, spermicidal and anti-infectious agents. The present invention also relates to methods of contraception using such a device, as well as the prevention and treatment of sexually transmitted diseases and vaginal infections through the application of the device.Type: GrantFiled: August 24, 2001Date of Patent: April 21, 2009Inventors: Brij B. Saxena, Mukul Singh, Sidney Lerner
-
Patent number: 7488594Abstract: The present invention relates to a chimeric nucleic acid molecule encoding a fusion protein having a human lutropin hormone-receptor domain and a human chorionic gonadotropin-? subunit domain, the isolated human lutropin hormone-receptor/human chorionic gonadotropin-? fusion protein, and antibodies which recognize part or all the domains of the fusion protein. Also provided are compositions having the human lutropin hormone-receptor/human chorionic gonadotropin-? fusion protein and a pharmaceutical carrier and compositions including antibodies to the fusion protein and a pharmaceutical carrier.Type: GrantFiled: September 26, 2005Date of Patent: February 10, 2009Assignee: Cornell Research Foundation, Inc.Inventors: Brij B. Saxena, Premila Rathnam, Mukul Singh, Meirong Hao
-
Publication number: 20080286291Abstract: The present invention relates to methods of treating HIV-1 infection in a subject. These methods involve administering to the subject with HIV-1 infection a therapeutically effective amount of a conjugated or immunoconjugated betulinol derivative compound, or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to treat the subject for HIV-1 infection. Also disclosed are methods inhibiting HIV-1 activity in a cell. These methods involve providing a cell infected with HIV-1 and contacting the cell with a conjugated or immunoconjugated betulinol derivative compound, or a pharmaceutically acceptable salt or derivative thereof, under conditions effective to inhibit HIV-1 activity in the cell.Type: ApplicationFiled: September 12, 2005Publication date: November 20, 2008Inventors: Brij B. Saxena, Premila Rathnam
-
Patent number: 6890533Abstract: The present invention is directed to betulinol derivatives and betulinol-antibody conjugates having the formulae: and HO-antibody-spacer-(A2)n and, in particular, betulinol dimethyl ether. Methods for making and using these derivatives and conjugates, as well as a method for making and using betulonic aldehyde, are also disclosed.Type: GrantFiled: June 3, 1998Date of Patent: May 10, 2005Assignee: Cornell Research Foundation, Inc.Inventors: Arkadiy L. Bomshteyn, Premila Rathnam, Brij B. Saxena
-
Patent number: 6723556Abstract: Purified hCG-hLH receptor, hCG-hLH receptor-hCG complex and combinations between their subunits as antigens, as well as antibodies thereto which are useful as a contraceptive vaccine. Antibodies to LH-R are useful in regulating steroid hormone production. Nucleic acid sequences encoding polypeptides with LH receptor activity were obtained and sequenced.Type: GrantFiled: September 14, 1993Date of Patent: April 20, 2004Assignee: Cornell Research Foundation, Inc.Inventors: Brij B. Saxena, Premila Rathnam
-
Publication number: 20040013730Abstract: The present invention relates to a non-hormonal, biocompatible, and biodegradable intravaginal device for the delivery of spermiostatic, spermicidal and anti-infectious agents. The present invention also relates to methods of contraception using such a device, as well as the prevention and treatment of sexually transmitted diseases and vaginal infections through the application of the device.Type: ApplicationFiled: July 31, 2003Publication date: January 22, 2004Inventors: Brij B. Saxena, Mukul Singh, Sidney Lerner
-
Publication number: 20040001837Abstract: The present invention is directed to betulinol derivatives and betulinol-antibody conjugates having the formulae: 1Type: ApplicationFiled: June 3, 1998Publication date: January 1, 2004Inventors: ARKADIY L. BOMSHTEYN, PREMILA RATHNAM, BRIJ B. SAXENA
-
Publication number: 20030036540Abstract: The present invention is directed to betulinol derivatives and betulinol-antibody conjugates having the formulae: 1Type: ApplicationFiled: August 2, 2002Publication date: February 20, 2003Inventors: Arkadiy L. Bomshteyn, Premila Rathnam, Brij B. Saxena
-
Patent number: 4966888Abstract: Purified hCG-hLH receptor, hCG-hLH receptor-hCG complex and combinations between their subunits as antigens, as well as antibodies thereto which are useful as a contraceptive vaccine.Type: GrantFiled: September 23, 1986Date of Patent: October 30, 1990Assignee: Cornell Research Foundation, Inc.Inventors: Brij B. Saxena, Premila Rathnam, Mukul Singh
-
Patent number: 4880914Abstract: A method to obtain a substantially pure and stable hLH-hCG receptor from gonadal cells is disclosed. The characteristics of the purified receptor are disclosed. The receptor, in addition to being used as receptor in an enzyme- or dye-receptor assay for hLH and/or hCG, can be used to purify hLH or hCG used in the preparation of standard dye-hormone or enzyme-hormone complexes. These complexes can be used in enzyme- or dye-immunoassays, as well as the receptor assay.Type: GrantFiled: September 23, 1985Date of Patent: November 14, 1989Assignee: Cornell Research Foundation, Inc.Inventors: Brij B. Saxena, Premila Rathnam
-
Patent number: 4693969Abstract: A reagent for use in a "sandwich" enzyme-immunoassay comprising a polymer of a bioactive substance-specific antibody:enzyme conjugate, wherein said antibody is conjugated to said enzyme by means of heterobifunctional cross-linking agent and a "sandwich" enzyme-immunoassay employing the polymer.Type: GrantFiled: May 4, 1984Date of Patent: September 15, 1987Assignee: Cornell Research Foundation, Inc.Inventors: Brij B. Saxena, Premila Rathnam
-
Patent number: 4560649Abstract: A method to obtain a substantially pure and stable hLH-hCG receptor from gonadal cells is disclosed. The characteristics of the purified receptor are disclosed. The receptor, in addition to being used as receptor in an enzyme- or dye-receptor assay for hLH and/or hCG, can be used to purify hLH or hCG used in the preparation of standard dye-hormone or enzyme-hormone complexes. These complexes can be used in enzyme- or dye-immunoassays, as well as the receptor assay.Type: GrantFiled: November 9, 1982Date of Patent: December 24, 1985Assignee: Cornell Research FoundationInventors: Brij B. Saxena, Premila Rathnam
-
Patent number: 4094963Abstract: Disclosed is a method for the determination of the hormone human chorionic gonadotropin (HCG), luteinizing hormone (LH), prolactin (PRL) and HCG-like material in an aqueous sample comprising contacting a highly specific receptor for these hormones with an aqueous sample to be tested, providing a means of indicating whether binding has taken place between the receptor and hormone possibly contained the sample and observing the indicating means to determine the presence of the hormone in the sample. PRL may be determined separately or simultaneously with the HCG and LH. The receptor is a plasma membrane extract from the corpus luteum of an animal which possesses the receptor for HCG, LH, PRL and HCG-like material. Radioassay indicating means are preferred, according to which competitive protein binding between radioisotopically labeled hormone and hormone present in the sample is radiologically determined. The method has particular application to the determination to pregnancy in the human female.Type: GrantFiled: May 20, 1976Date of Patent: June 13, 1978Assignee: Cornell Research Foundation, Inc.Inventor: Brij B. Saxena
-
Patent number: 4016250Abstract: Method for the determination of the hormone human chorionic gonadotropin (HCG), luteinizing hormone (LH), prolactin (PRL) and HCG-like material in an aqueous sample comprising contacting a highly specific receptor for these hormones with an aqueous sample to be tested, providing a means of indicating whether binding has taken place between the receptor and hormone possibly contained in the sample and observing the indicating means to determine the presence of the hormone in the sample. PRL may be determined separately or simultaneously with the HCG and LH. The receptor is a plasma membrane extract from the corpus luteum of an animal which possesses the receptor for HCG, LH, PRL and HCG-like material. Radioassay indicating means are preferred, according to which competitive protein binding between radioisotopically labeled hormone and hormone present in the sample is radiologically determined. The method has particular application to the determination to pregnancy in the human female.Type: GrantFiled: November 11, 1974Date of Patent: April 5, 1977Assignee: Cornell Research Foundation, Inc.Inventor: Brij B. Saxena